NEW YORK (GenomeWeb) – Santa Cruz, California-based Two Pore Guys said today that it is collaborating with oncologists at the University of California, San Francisco to develop a liquid biopsy assay. The UCSF team plans to evaluate Two Pore Guys' handheld nanopore platform for detecting circulating tumor DNA, and specifically, for detecting a KRAS mutation from blood and urine samples.

Andrew Ko, a professor of hematology and oncology and gastrointestinal cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center, will lead the study.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.

Aug
09
Sponsored by
Agena Bioscience

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug
15
Sponsored by
Swift Biosciences

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.